[go: up one dir, main page]

MX2010007670A - Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales. - Google Patents

Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales.

Info

Publication number
MX2010007670A
MX2010007670A MX2010007670A MX2010007670A MX2010007670A MX 2010007670 A MX2010007670 A MX 2010007670A MX 2010007670 A MX2010007670 A MX 2010007670A MX 2010007670 A MX2010007670 A MX 2010007670A MX 2010007670 A MX2010007670 A MX 2010007670A
Authority
MX
Mexico
Prior art keywords
treatment
viral infections
acetylsalicylic acid
acid salt
salt
Prior art date
Application number
MX2010007670A
Other languages
English (en)
Inventor
Stephan Ludwig
Gerhard Scheuch
Oliver Planz
Original Assignee
Activaero Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activaero Gmbh filed Critical Activaero Gmbh
Publication of MX2010007670A publication Critical patent/MX2010007670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención es concerniente con el uso de una composición que comprende una sal del ácido o-acetilsalicílico con un aminoácido básico para producir una composición farmacéutica para la profilaxis o tratamiento de infecciones virales humanos o de animales, en particular mamíferos y aves.
MX2010007670A 2008-01-14 2009-01-14 Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales. MX2010007670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008004386A DE102008004386A1 (de) 2008-01-14 2008-01-14 Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
PCT/DE2009/000033 WO2009089822A2 (de) 2008-01-14 2009-01-14 Verwendung eines acetylsalicylsäuresalzes zur behandlung viraler infektionen

Publications (1)

Publication Number Publication Date
MX2010007670A true MX2010007670A (es) 2010-10-08

Family

ID=40765574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007670A MX2010007670A (es) 2008-01-14 2009-01-14 Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales.

Country Status (20)

Country Link
US (1) US9492413B2 (es)
EP (1) EP2249866B1 (es)
JP (1) JP2011509928A (es)
KR (1) KR20100103845A (es)
CN (2) CN105477005A (es)
AU (1) AU2009204574B2 (es)
BR (1) BRPI0906851B1 (es)
CA (1) CA2714286C (es)
DE (1) DE102008004386A1 (es)
DK (1) DK2249866T3 (es)
ES (1) ES2392379T3 (es)
HR (1) HRP20120812T1 (es)
IL (1) IL206450A (es)
MX (1) MX2010007670A (es)
PL (1) PL2249866T3 (es)
PT (1) PT2249866E (es)
RU (1) RU2524304C2 (es)
SI (1) SI2249866T1 (es)
WO (1) WO2009089822A2 (es)
ZA (1) ZA201004888B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
CN107073123A (zh) * 2014-05-16 2017-08-18 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
DE102014111892A1 (de) 2014-08-20 2016-02-25 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer Infektion mit dem Hantavirus
WO2017109037A1 (en) * 2015-12-22 2017-06-29 Ventaleon Gmbh Treatment of moderate to severe influenza
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
US10882811B2 (en) * 2016-12-23 2021-01-05 Aspiair Gmbh Synthesis of lysine acetylsalicylate glycine particles
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR20220055697A (ko) 2020-10-27 2022-05-04 강원대학교산학협력단 살리신을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4856815A (es) 1971-11-13 1973-08-09
ATE179605T1 (de) * 1991-02-09 1999-05-15 B S D Bio Science Dev Snc Di O Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
BE1010692A6 (nl) * 1996-10-15 1998-12-01 Fogel Raphiel Aerosoldoseerinrichting en spuitkap hierbij aangewend.
GB2306109B (en) 1997-02-07 1997-09-24 John Wright A zinc containing composition as a common cold prophylactic
RU2131750C1 (ru) * 1997-11-21 1999-06-20 Фролов Владимир Федорович Дыхательный тренажер
US20020064542A1 (en) 1999-06-29 2002-05-30 George Endel Deckner Tissue products utilizing water soluble films as carriers for antiviral compositions and process for making
DE10029119B4 (de) 2000-06-14 2005-12-22 Institut für Aerosol Medizin InAMed GmbH Inhalationsvorrichtung
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
DE10123749A1 (de) 2001-05-16 2002-12-12 Inamed Gmbh Vorrichtung zum Verabreichen von Aerosolen
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
CN1561396A (zh) * 2001-09-27 2005-01-05 株式会社载体研究所 调节病毒载体所携带的基因的表达的方法
DE10202019A1 (de) 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
CN1418635A (zh) * 2002-12-19 2003-05-21 王登之 治疗感冒发热的阿司匹林口腔崩解片及其制备方法
DE10300222A1 (de) 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
DE10313636A1 (de) 2003-03-26 2004-10-14 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
EP1700614B1 (de) 2005-03-08 2013-05-08 Activaero GmbH Inhalationsvorrichtung
ITMI20050417A1 (it) * 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
ES2290827T3 (es) 2005-07-06 2008-02-16 Activaero Gmbh Valvula regulable y dispositivo para inhalar.
DE102005053358A1 (de) * 2005-11-07 2007-05-10 Lenk, Norbert, Dr. Vorrichtung zur gesteuerten Bereitstellung von Ozon

Also Published As

Publication number Publication date
CN105477005A (zh) 2016-04-13
AU2009204574A1 (en) 2009-07-23
WO2009089822A2 (de) 2009-07-23
KR20100103845A (ko) 2010-09-28
SI2249866T1 (sl) 2012-11-30
HK1144553A1 (en) 2011-02-25
HRP20120812T1 (hr) 2012-11-30
RU2010133870A (ru) 2012-04-20
BRPI0906851A2 (pt) 2020-08-18
US20120017892A1 (en) 2012-01-26
PT2249866E (pt) 2012-11-05
CN101909650A (zh) 2010-12-08
US9492413B2 (en) 2016-11-15
EP2249866B1 (de) 2012-08-15
ZA201004888B (en) 2011-04-28
WO2009089822A3 (de) 2010-02-25
BRPI0906851B1 (pt) 2022-02-08
CA2714286A1 (en) 2009-07-23
RU2524304C2 (ru) 2014-07-27
IL206450A0 (en) 2010-12-30
CA2714286C (en) 2016-05-24
AU2009204574B2 (en) 2014-05-29
PL2249866T3 (pl) 2012-12-31
DK2249866T3 (da) 2012-10-22
JP2011509928A (ja) 2011-03-31
EP2249866A2 (de) 2010-11-17
ES2392379T3 (es) 2012-12-10
DE102008004386A1 (de) 2009-07-23
IL206450A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
MX2010007670A (es) Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales.
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
EA201270567A1 (ru) Противомикробные соединения и способы их получения и применения
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
EA201391536A1 (ru) Противомикробные соединения и способы их получения и применения
MX2011009847A (es) Agentes antihelminticos y su uso.
EA201270216A1 (ru) Фармацевтический состав
BR112015029970A2 (pt) inibidores de cinase
NZ597510A (en) NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2013000730A1 (es) Proceso para preparar compuestos derivados de dihidropteridinonas, moduladores de la quinasa tipo polo plk-1, útiles para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes; procesos de preparacion de compuestos intermediarios.
MX2014001600A (es) 3,4-dihidro-1h-[1,8]naftiridinosas antibacterianas sustituidas con ciclopenta[c]pirrol.
JO2581B1 (en) Aryl sulfonomides replaced
IN2014CN00572A (es)
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
EA201500913A1 (ru) Противомикробные соединения и способы их получения и применения
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights